Alzheimer's Biomarker Initiative to Improve Trials and Care
Official title: Alzheimer's Disease Neuroimaging Initiative (ADNI4)
Funded at Northern California Institute/res/edu · NIH-11592262 · Data updated 2026-11-12
A large study to validate biomarkers for Alzheimer’s disease and improve how future trials recruit and monitor people at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern California Institute/res/edu NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 30, 2004 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $19,101 |
| NIH project number | 3U19AG024904-19S3 |
| Project ID | NIH-11592262 on NIH RePORTER |
Who could benefit from this research
✓Could help
Eligible participants include individuals at higher risk for dementia and those already enrolled in earlier ADNI cohorts who may contribute data and samples.
✕Less likely to help
Direct care for patients is not the primary focus; however, trial design improvements may indirectly benefit future patients.
What this research studies
This project continues to collect and share imaging, cognitive, genetic, and biomarker data to support Alzheimer’s trials and understanding of disease progression. It plans to follow hundreds of participants and recruit individuals at higher risk for dementia using digital and in-person outreach. Data and samples will be made widely available to researchers to accelerate discovery and trial design.
Why it matters
Potential benefit: If successful, the work could speed development of effective Alzheimer’s therapies and safer, faster clinical trials.
How similar studies have gone: ADNI has a long track record of influencing successful trial designs and biomarker validation in Alzheimer’s research.
Where this research is happening
-
Northern California Institute/res/edu
San Francisco, United States Active
Researchers
- Principal investigator: Weiner, Michael W — Northern California Institute/res/edu
- Study coordinator: Weiner, Michael W
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.